Full-Time

Associate Vice President Head of Enterprise Risk

Enterprise Risk Management

Posted on 9/17/2025

Deadline 8/12/26
HealthEquity

HealthEquity

1-10 employees

Manages HSAs and consumer-directed benefits

Compensation Overview

$151.5k - $220.6k/yr

+ Performance-based incentives + Restricted stock units

Remote in USA

Remote

Category
Finance & Banking (1)
Requirements
  • Advanced degree preferred (MBA, PhD, quantitative master’s); JD considered if risk-focused.
  • 12+ years in financial/operational risk management, ideally within regulated financial services or consulting.
  • 5–7 years in a leadership role with board-level exposure.
  • Proven success in enterprise risk management, especially in financial services (banking, investment, insurance, fintech).
  • Experience with regulators (e.g., Fed, OCC, FDIC) or large institutions is a plus.
  • Deep knowledge of risk frameworks, tools, and regulatory requirements.
  • Ability to influence and challenge constructively at the highest levels.
  • Strong communication and stakeholder management skills—able to speak truth to power with diplomacy.
  • Professional certifications (e.g., FRM, CFA) are advantageous.
Responsibilities
  • Lead and evolve the ERM program with a focus on continuous improvement.
  • Partner across business units to support and challenge risk owners, and occasionally lead crisis management efforts.
  • Present risks and mitigation strategies to senior leadership, influencing priorities and resource allocation.
  • Own and enhance key ERM components: risk registers, appetite frameworks, key risk indicators, stress tests, and dashboards.
  • Stay ahead of the curve on external threats, macroeconomic trends, and regulatory shifts.
  • Drive alignment between ERM and strategic planning, budgeting, project prioritization, and regulatory reporting.
  • Collaborate deeply with Compliance, Privacy, Internal Audit, and other assurance teams to strengthen risk mitigation.
  • Champion risk awareness and continuous improvement across the organization.
Desired Qualifications
  • Experience with regulators (e.g., Fed, OCC, FDIC) or large institutions is a plus.
  • Professional certifications (e.g., FRM, CFA) are advantageous.

HealthEquity administers Health Savings Accounts (HSAs) and other consumer-directed benefits such as FSAs, HRAs, COBRA, and Commuter plans for more than 16 million members. Its system handles account setup, eligibility, contributions, investments, claims, and reimbursements, with a digital interface for members to manage funds and understand eligible expenses. The company differentiates itself through its large scale, focus on consumer-directed benefits, and combination of technology-enabled tools with attentive service. Its goal is to simplify and optimize health-related savings and benefits to help people manage medical costs and improve long-term financial wellbeing.

Company Size

1-10

Company Stage

IPO

Headquarters

Draper, Utah

Founded

2002

Simplify Jobs

Simplify's Take

What believers are saying

  • Record 550K new HSAs in Q4 2026 drove net income up 89% to $49.7M.
  • HSA assets grew 14% to $36B, with FY2027 revenue guidance $1.405-1.415B.
  • $457M operating cash flow in FY2026 funds $2B WageWorks acquisition.

What critics are saying

  • Insider sales by EVP Delano Ladd (6,000 shares) signal executive doubt.
  • Optum Bank bundles HSAs with insurance, capturing 15% market share by 2027.
  • WageWorks $2B acquisition disrupts operations, causes customer churn in 2026-2027.

What makes HealthEquity unique

  • HealthEquity administers 17.8 million HSAs, largest independent custodian by volume.
  • GLP-1 telehealth platform launched October 2025 enables direct HSA payments for weight-loss drugs.
  • Bill Gassen, Sanford Health CEO, joined board March 26, 2026, enhancing healthcare expertise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Paid Vacation

Paid Holidays

Paid Parental Leave

401(k) Company Match

Professional Development Budget

Gym Membership

Wellness Program

Company News

Stock Titan
Mar 30th, 2026
Sanford Health CEO joins HealthEquity (NASDAQ: HQY) board, expanding it to 10.

Sanford Health CEO joins HealthEquity (NASDAQ: HQY) board, expanding it to 10. Filing Impact (Moderate) Filing Sentiment Rhea-AI Filing summary. HealthEquity, Inc. appointed William "Bill" Gassen, president and chief executive officer of Sanford Health, to its board of directors effective March 26, 2026. His appointment increases the board size to ten directors, eight of whom are independent. Gassen will serve on the Board's Audit and Risk Committee and Talent, Compensation and Culture Committee HealthEquity received $123,923 in revenue from Sanford Health for consumer-directed benefits during the fiscal year ended January 31, 2026, and expects revenue from Sanford Health in the fiscal year ending January 31, 2027 to exceed $120,000. The company furnished a press release about Gassen's appointment as an exhibit. 8-K Event Classification 3 items: 5.02, 7.01, 9.01 3 items Key Figures Board size after appointment: 10 directors Independent directors count: 8 independent directors Revenue from Sanford Health FY 2026: $123,923 +3 more 6 metrics Key Terms Audit and Risk Committee, Talent, Compensation and Culture Committee, Non-Employee Director Compensation Policy, indemnification agreement, +2 more 6 terms Understanding 8-K Material Events | 03/30/2026 - 05:38 PM Source: View Original Filing on SEC EDGAR FAQ What board change did HealthEquity (HQY) announce in this 8-K? HealthEquity appointed William "Bill" Gassen, CEO of Sanford Health, to its board effective March 26, 2026. His appointment expands the board to ten directors, strengthening governance depth while keeping eight directors classified as independent under applicable standards. What committees will Bill Gassen serve on at HealthEquity (HQY)? Bill Gassen will serve on HealthEquity's Audit and Risk Committee and its Talent, Compensation and Culture Committee. These assignments place him at the center of the company's financial oversight, risk management, and executive pay and culture discussions at the board level. Does HealthEquity (HQY) have a business relationship with Sanford Health? Yes. HealthEquity received $123,923 in revenue from Sanford Health in the fiscal year ended January 31, 2026 for consumer-directed benefits and expects revenue exceeding $120,000 in the fiscal year ending January 31, 2027 from that ongoing customer relationship. How will Bill Gassen be compensated for serving on HealthEquity's board? Bill Gassen will receive standard non-employee director compensation under HealthEquity's Non-Employee Director Compensation Policy. This includes board retainer fees and additional annual equity awards, consistent with what other non-employee directors receive for their service. How large is HealthEquity's board and how many directors are independent? After Bill Gassen's appointment, HealthEquity's board consists of ten directors, up from nine previously. Eight of these ten directors are described as independent, reflecting the company's emphasis on independent oversight in its governance structure. How many accounts does HealthEquity (HQY) administer and what is its focus? HealthEquity and its subsidiaries administer health savings accounts and other consumer-directed benefits for more than 17 million accounts. The company partners with employers, advisors, and plan providers to help people save for and pay for healthcare expenses more effectively. Filing Exhibits & Attachments 4 documents Press Releases * EX-99.1 EX-99.1 6.3 KB Other Documents * EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB * EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.3 KB * EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.8 KB

The Associated Press
Mar 30th, 2026
HealthEquity appoints Sanford Health CEO Bill Gassen to board of directors

HealthEquity has appointed Bill Gassen, president and chief executive officer of Sanford Health, to its board of directors effective 26 March 2026. Gassen will serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee, expanding the board to 10 directors, eight of whom are independent. Gassen has led Sanford Health, the nation's largest rural health system, since November 2020. He previously held senior roles at Sanford Health including chief administrative officer and chief human resources officer. He also serves on the board of Oscar Health and holds a bachelor's degree in criminal justice and a J.D. from the University of South Dakota. HealthEquity is the largest independent health savings account custodian by account volume, administering accounts for over 17 million customers.

AD HOC NEWS Portal Aktiengesellschaft
Mar 24th, 2026
HealthEquity Inc stock faces pressure amid insider sales and GLP-1 platform launch on NASDAQ.

HealthEquity Inc stock faces pressure amid insider sales and GLP-1 platform launch on NASDAQ. 24.03.2026 - 07:27:47 | ad-hoc-news.de HealthEquity Inc (ISIN: US42226C1071) shares traded at $81.02 USD on NASDAQ as of March 23, 2026, following recent executive stock sales and the rollout of new GLP-1 telehealth and HSA enrollment platforms. US investors eye growth in health savings accounts amid rising healthcare costs. HealthEquity Inc stock on NASDAQ has come under scrutiny after multiple insider sales by executives, even as the company launched innovative platforms for GLP-1 telehealth and direct HSA enrollment. These developments, announced in mid-October 2025, aim to expand access to weight-loss medications and streamline health savings account management for millions of users. For US investors, this mix of product innovation and insider activity signals both growth potential in the booming HSA market and caution over short-term valuation pressures, with shares last at $81.02 USD on March 23, 2026. As of: 24.03.2026 By Dr. Elena Voss, Senior HealthTech Analyst - HealthEquity Inc's push into GLP-1 services positions it at the intersection of digital health and rising obesity treatment demand, a key watchpoint for investors tracking HSA market leaders. Recent platform launches drive strategic expansion. HealthEquity Inc introduced a GLP-1 telehealth platform and direct HSA enrollment tools in October 2025, targeting its vast user base of health savings account holders. These initiatives allow members to access affordable healthcare solutions for popular weight-loss drugs like GLP-1 agonists through a curated digital interface. The move capitalizes on surging demand for obesity treatments, where US prescription volumes have skyrocketed post-regulatory approvals. Company executives highlighted how these platforms integrate seamlessly with existing HSA funds, enabling direct payments for telehealth consultations and medications. This positions HealthEquity as a one-stop shop for healthcare spending decisions, potentially boosting user retention and fee revenues. For the healthtech sector, such integrations underscore the shift toward consumer-centric platforms amid escalating healthcare expenses. Market reaction was initially positive, with shares up 5.5% following the announcement, reflecting optimism over new revenue streams. However, sustained price stagnation ensued, with the stock trading in a 52-week range of $73.21 to $113.06 USD on NASDAQ. Investors now assess whether these launches can reverse recent downward momentum. Official source Find the latest company information on the official website of HealthEquity Inc. Insider selling raises eyebrows among investors. Several HealthEquity executives offloaded shares in recent months, including EVP sales totaling over $138,000 and another transaction of $157,000. Notable transactions involved EVP Delano Ladd selling 6,000 shares and Michael Henry Fiore divesting 1,781 shares. These moves occurred against a backdrop of stock price consolidation around $81 USD on NASDAQ. While insider sales do not necessarily signal pessimism, the timing coincides with post-earnings weakness, where shares dropped 5.1% since the last report. Institutional activity is mixed, with firms like Stephens Investment Management reducing positions while others like Sequoia Financial Advisors increased holdings. This divergence prompts questions on internal confidence versus opportunistic profit-taking. For US investors, monitoring insider trends provides insight into management alignment with shareholders. HealthEquity's leadership, including CEO Scott R. Cutler, has navigated the company through growth phases, but recent sales amplify focus on upcoming quarterly results. Sentiment and reactions HSA market dynamics and HealthEquity's positioning. HealthEquity Inc dominates the health savings account administration space, serving over three million accounts with a platform that manages billions in assets. Headquartered in Draper, Utah, the company founded in 2002 focuses on technology-enabled services for healthcare spending. Its market cap stands at approximately $8.28 billion, with a price-to-earnings ratio of 58.22 reflecting high growth expectations. The HSA sector benefits from US tax-advantaged accounts gaining traction as healthcare costs rise. HealthEquity's average daily volume hovers around 858,000 shares on NASDAQ, indicating solid liquidity for investors. Recent platforms enhance stickiness by linking HSAs to emerging needs like GLP-1 therapies, which address the obesity epidemic affecting 42% of Americans. Competitive edges include robust custodial services and custodial banking partnerships, ensuring compliance and security. As employers shift to high-deductible plans, HealthEquity captures recurring custodial fees and interchange revenues, key metrics for sector profitability. Why US investors should watch closely now. US investors stand to gain from HealthEquity's alignment with megatrends in preventive healthcare and digital payments. GLP-1 launches tap into a market projected to exceed $100 billion by 2030, where HSA compatibility differentiates leaders. Shares at $81.02 USD on NASDAQ offer a potential 37.77% upside per some analyses, driven by earnings recovery. Analyst consensus leans toward 'Moderate Buy,' with focus on HSA initiatives reshaping growth narratives. For German-speaking investors in Germany, Austria, and Switzerland, exposure via US markets provides diversification into resilient healthtech, less correlated to European cyclicals. Currency-hedged ETFs or direct NASDAQ access via brokers like Interactive Brokers facilitate participation. Quarterly catalysts include membership growth and assets under management expansion, vital for fee-based models. With no dividend yet, total returns hinge on capital appreciation amid sector tailwinds. Analyst views and valuation considerations. Brokerages rate HealthEquity as a 'Buy,' citing durable growth in HSA penetration. Recent reports note potential rebound post-earnings dip, with shares down 4.5% prompting buy-the-dip opportunities. Trading at a premium P/E reflects expectations of 15-20% annual revenue growth from platform expansions. Key risks include regulatory changes to HSAs or GLP-1 coverage under insurance plans. Balance sheet strength supports acquisitions, as seen in past tuck-ins bolstering scale. Investors weigh high valuation against market leadership, with 52-week highs at $116.65 USD signaling upside room. Comparative analysis versus peers like Benefitfocus or WageWorks highlights HealthEquity's superior scale and innovation pace. Forward estimates emphasize margin expansion from digital efficiencies. Further reading Further developments, updates, and context on the stock can be explored quickly through the linked overview pages. Risks and open questions ahead. Primary risks include execution on new platforms amid competition from pharmacy benefit managers. Insider sales could foreshadow earnings misses if user adoption lags. Macro headwinds like recessionary pressures on elective healthcare spending pose threats to custodial inflows. Regulatory scrutiny on GLP-1 pricing and HSA eligibility remains a wildcard, potentially curbing growth. High debt levels from past deals necessitate vigilant cash flow monitoring. Investors question sustainability of premium multiples if growth moderates below 15%. Geopolitical factors indirectly impact via supply chain for medications, though HealthEquity's service model buffers direct exposure. Long-term, demographic aging supports demand, but near-term volatility warrants position sizing discipline. Strategic outlook and investor roadmap. HealthEquity's roadmap emphasizes API integrations and AI-driven personalization for HSAs, enhancing user engagement. Partnerships with telehealth providers accelerate GLP-1 rollout, targeting 10 million potential users. M&A remains a lever for inorganic growth in fragmented markets. For US investors, the stock suits growth-oriented portfolios with healthtech conviction. Entry points near current levels balance risk-reward, pending positive earnings inflection. German-speaking investors benefit from NASDAQ's transparency and liquidity. Sustained focus on metrics like net revenue retention above 95% and account growth over 5% annually underpins bull case. Bear scenarios hinge on margin compression from tech investments. Disclaimer: This is not investment advice. Stocks are volatile financial instruments. Android-Warnung 2026: Millionen Nutzer unterschätzen diese 3 Sicherheitslücken. Kostenloser Check vom 27. März: WhatsApp-Backup unverschlüsselt? Banking-App ohne Schutz? WLAN-Verbindung offen? Diese drei Fehler machen Ihr Android-Handy zum leichten Ziel für Hacker. Das kostenlose Sicherheitspaket zeigt Ihnen in 5 einfachen Schritten, wie Sie jede Lücke schließen - bevor es jemand anderes für Sie tut. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen - dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren. Für. Immer. Kostenlos. US42226C1071 | HEALTHEQUITY INC | boerse | 68972564 | bgmi

Yahoo Finance
Mar 18th, 2026
HealthEquity reports record 550K new HSAs in Q4, net income surges 89% to $49.7M

HealthEquity reported strong Q4 2026 results, with revenue increasing 7% year-over-year to $334.6 million and net income surging 89% to $49.7 million. Adjusted EBITDA grew 23% with margin expansion exceeding 500 basis points. The company added a record 550,000 Health Savings Accounts in Q4, bringing total HSA accounts to 17.8 million. HSA assets increased 14% to over $36 billion, whilst gross margin expanded to 68% from 61% the previous year. HealthEquity generated $457 million in cash flow from operations in fiscal 2026 and returned over $300 million to shareholders through share repurchases, reducing diluted shares by approximately 3%. For fiscal 2027, the company expects revenue between $1.405 and $1.415 billion, with adjusted EBITDA guidance of $618 to $628 million.

INACTIVE